Online Abstracts Vaccines - Impact of Vaccine programs and Serotype Replacement C2 Impact of Vaccine programs and Serotype Replacement

PCV15 AND PPSV23 COVERAGE OF INVASIVE AND RESPIRATORY TRACT ISOLATES OF STREPTOCOCCUS PNEUMONIAE: CANWARD 2007-2018

Presentation Type
Abstract_Submission
Presentation Topic
C2 Impact of Vaccine programs and Serotype Replacement

Abstract

Background

The objective of this study was to compare the proportion of invasive and respiratory tract isolates of Streptococcus pneumoniae (SPN), including multidrug/extensive-drug resistant (MDR/XDR) strains, that demonstrated PCV15/PPSV23 serotypes in Canada from 2007-2018.

Methods

The CANWARD study collected 2821 SPN isolates from 2007-2018 (986 invasive, 1835 respiratory). Serotyping was performed by the Quellung reaction. Antimicrobial susceptibility testing was performed using CLSI methods. MDR/XDR was defined as resistance to ³3/³5 antimicrobial classes, respectively.

Results

Overall, the proportion of blood isolates demonstrating a PCV15/PPSV23 serotype was significantly higher than respiratory strains (55.4/76.7% vs 39.5/55.3%, P<0.0001). By age group, with the exception of the <2-year category, the proportion of blood isolates demonstrating a PCV15/PPSV23 serotype was significantly higher than respiratory strains (P</=0.0046). Similar results were noted by gender (P<0.0001) and region (P</=0.0002), with the exception of Eastern Canada. There was no significant difference in the proportion of MDR blood (64.4/71.1%) and respiratory (54.3/56.1%) isolates representing PCV15/PPSV23 serotypes, respectively. All XDR isolates were serotypes contained in PCV15/PPSV23, and there was no significant difference in proportion between blood (92.9%) and respiratory (88.9%) isolates.

Conclusions

In general, the proportion of blood isolates demonstrating a PCV15/PPSV23 serotype in Canada was significantly higher than that of respiratory isolates.

Hide